Remisja cukrzycy typu 2 po leczeniu bariatrycznym — porównanie różnych procedur

Fernández-Soto, María Luisa; Martín-Leyva, Ana; González-Jiménez, Amalia; García-Rubio, Jesús; Cózar-Ibáñez, Antonio; Zamora‐Camacho, Francisco Javier; Leyva-Martínez, María S; Jiménez-Ríos, José Antonio; Escobar-Jiménez, Fernándo

doi:10.5603/ep.2017.0004

Cited by 16 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently published results of a meta-analysis underline the hypothetical positive effects of bariatric procedures on the control of glucose metabolism and improvements of normoglycaemia in diabetic patients [86][87][88].…”

Section: Resultsmentioning

confidence: 99%

Endokrynne implikacje otyłości i zabiegów bariatrycznych

Dyaczyński

Scanes

Koziec

et al. 2018

Endokrynologia Polska

View full text Add to dashboard Cite

Obesity is a highly prevalent disease in the world associated with the disorders of endocrine system. Recently, it may be concluded that the only effective treatment of obesity remains bariatric surgery. The aim of the review was to compare the concepts of appetite hormonal regulation, reasons of obesity development and bariatric procedures published over the last decade. The reviewed publications had been chosen on the base on: 1. reasons and endocrine consequences of obesity; 2. development of surgery methods from the first bariatric to present and future less aggressive procedures; 3. impact of surgery on the endocrine status of patient. The most serious endocrine disturbances during obesity are dysfunctions of hypothalamic circuits responsible for appetite regulation, insulin resistance, changes in hormones activity and abnormal activity of adipocytes hormones. The currently recommended bariatric surgeries are Roux-en-Y gastric bypass, sleeve gastrectomy and adjustable gastric banding. Bariatric surgical procedures, particularly combination of restrictive and malabsorptive, decrease the body weight and eliminate several but not all components of metabolic syndrome. Conclusions: 1. Hunger and satiety are mediated by an interplay of nervous and endocrine signals. 2. Healthy adipose tissue secretion of adipokines is coordinated in an anti-inflammatory, insulin-sensitizing and cardioprotective pattern. However, with increasing fat mass this secretion pattern is changed into a proinflammatory, insulin resistant, atherogenic and fatal systemic environment. 3. Bariatric surgery is not a solution of the obesity problem for everyone. 4. Long term postsurgical observations of the hormonal profile changes are necessary and should be obligatory.

show abstract

Section: Resultsmentioning

confidence: 99%

Endokrynne implikacje otyłości i zabiegów bariatrycznych

Dyaczyński

Scanes

Koziec

et al. 2018

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…Contrary to other studies, they concluded that there was no difference in T2DM remission rates after the three procedures, and a substantial 80% of patients had remitted at a one-year follow-up. They mention that this finding could be because only morbidly obese (BMI >50.2kg/m 2 ) patients were included in their study, as opposed to other studies (which include patients with lower BMIs) that show a clear superiority of RYGB over other procedures [ 28 ]. This finding from the Fernández-Soto et al study can be compared with results from Behbehani et al, where participants had a BMI >50.3kg/m 2 and RYGB was still the dominant procedure for attaining remission.…”

Section: Reviewmentioning

confidence: 99%

Bariatric Surgery and Type 2 Diabetes Mellitus: Assessing Factors Leading to Remission. A Systematic Review

Ilyas

Al-Refai

Maharjan

et al. 2020

Cureus

View full text Add to dashboard Cite

Type 2 Diabetes Mellitus (T2DM) is a health problem of paramount proportions and is associated with significant morbidity and mortality. Our study aims to review data published on the effects of different types of bariatric surgeries on T2DM remission, compared to lifestyle and medical intervention (LMI) exclusively, along with a comprehensive finding of numerous preoperative factors that lead to remission. We used PubMed, PubMed Central (PMC), and MEDLINE to search for literature. Our criteria included peer-reviewed, English language articles published in 2010 and onwards, consisting of adults with T2DM and a body mass index (BMI) of >30 kg/m 2 as the population of interest. Twenty-four articles with 5,411 patients were selected for this systematic review, which included nine randomized controlled trials (RCTs) and 15 observational studies. The primary endpoint was T2DM remission. Based on the review, bariatric surgery is superior to LMI in inducing remission in T2DM, especially when employing the Roux-en-Y Gastric Bypass (RYGB) technique. Lower age of onset and shorter duration of T2DM, along with a high BMI are some of the factors that can lead to greater remission rates. Further research in RCTs is needed by incorporating double/triple-blind protocols, a standard definition of T2DM remission, long follow-up periods to evaluate for relapses in remission and any side effects, with a focus on inflammatory markers (eg, osteopontin), scoring systems (eg, DiaRem), and benefits of One-Anastomosis Gastric Bypass (OAGB) over other modalities, to advance our understanding of T2DM remission.

show abstract

“…III) [21]. Despite the high efficacy and safety of bariatric surgeries [22][23][24], they are still not a frequently chosen therapeutic option by patients and physicians, especially because of the limited availability of bariatric surgery centres. Taking these facts into account, pharmacotherapy becomes an important aspect of obesity treatment.…”

Section: Obesity Treatmentmentioning

confidence: 99%

Farmakoterapia otyłości — obecny stan wiedzy

Matyjaszek‐Matuszek

Szafraniec

Porada

2018

Endokrynologia Polska

View full text Add to dashboard Cite

Obesity, which affects about 13% of the world population, results in significant deterioration of health and serious clinical, mainly meta-bolic and cardiovascular complications. Although the basis of therapeutic treatment is behavioural treatment, often non-pharmacological effects do not produce the desired effect. Currently there are several drugs with a safe action profile that improve the effect of treatment (5-10% weight reduction). The aim of the paper is to present the potential of modern pharmacotherapy in the treatment of obesity, in terms of mechanism of action, efficacy, and side effects, in order to individualise therapy. The drugs already registered include substances with a variety of mechanisms of action, including phentermine, orlistat, lorcaserin, and liraglutide. Compounded preparations (phenter-mine/topiramate, naltrexone SR/bupropion SR) are also available, which, by using low doses of active substances, have beneficial effects while reducing side effects. In addition, several drugs used to treat diabetes, such as metformin, SGLT2 inhibitors, GLP-1 agonists, and pramlintide, promote weight loss, although their use is reserved for diabetics, especially type 2 patients. Regarding the current alarm-ing epidemiological data there is a need for intensive prevention and treatment of obesity as well as the development of a new form of pharmacotherapy (new substances and treatment regimens) to develop effective, safe, and, above all, long-term effective therapy for the treatment of obesity.

show abstract

Remisja cukrzycy typu 2 po leczeniu bariatrycznym — porównanie różnych procedur

Cited by 16 publications

References 35 publications

Endokrynne implikacje otyłości i zabiegów bariatrycznych

Endokrynne implikacje otyłości i zabiegów bariatrycznych

Bariatric Surgery and Type 2 Diabetes Mellitus: Assessing Factors Leading to Remission. A Systematic Review

Farmakoterapia otyłości — obecny stan wiedzy

Contact Info

Product

Resources

About